This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.
Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery
This Might Also Be of Interest
Nasal Delivery of Biologics: A Whole New Ball Game
Webinars, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations
Case Study – Unidose Nasal Spray Pump for Epilepsy
Case Studies, Pharmaceutical, Market Insights, Product Solutions, Drug Delivery Innovations
Building Digital Solutions To Meet The Unique Therapeutic Needs of Patients
Publications, Pharmaceutical, Innovation & Insights, Drug Delivery Innovations, Product Solutions
Drug Repositioning – Benefits and Challenges for Lifecycle Management
Webinars, Pharmaceutical, Drug Delivery Innovations, Brand Differentiation, Market Insights, Product Solutions
